Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001219454 | SCV001391394 | pathogenic | Actin accumulation myopathy | 2023-11-27 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with lysine, which is basic and polar, at codon 94 of the ACTA1 protein (p.Asn94Lys). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with autosomal dominant congenital myopathy (PMID: 21514153, 28416349). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 948238). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ACTA1 protein function with a negative predictive value of 80%. This variant disrupts the p.Asn94 amino acid residue in ACTA1. Other variant(s) that disrupt this residue have been observed in individuals with ACTA1-related conditions (PMID: 19562689), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. |